Items tagged with Access

India: TB control: five key reasons to engage the private sector (post)

India accounts for a quarter of the 8.6 million cases of TB that occur worldwide. India also accounts for a third of the ‘missing 3 million TB cases’ that do not get diagnosed or notified. Not only is TB not going away, we are now seeing severe forms of multidrug-resistant TB (MDR-TB).

Thailand: Thousands with TB lack treatment (post)

A third of tuberculosis (TB) sufferers in Thailand are not receiving proper treatment, increasing the risk of spreading the disease and their chances of becoming resistant to multiple treatment drugs.

Story from Moldova: TB for 20 years with no hope of recovery (post)

Chased by tuberculosis for more than twenty years, Igor (42), from the small town Anenii Noi in Moldova, lives in dark hopelessness for a recovery. His wife has passed away and his children have been taken to a specialised institution.

Report: ECAB meeting on HIV/TB coinfection, May 17-19, 2013 (post)

The purpose of the report, based on the TB ECAB (European Community Advisory Board) meeting held in Brussels between May 17-19, 2013 is to inform ECAB and community advocates on HIV/TB treatment, care and research advocacy, in order to increase the capacity of the ECAB members and partners to get further involved in TB drugs, diagnostics development and access, and to identify key advocacy priorities.

Cooperation over local manufacturing of pharmaceuticals in Africa intensifies (post)

GENEVA/ABUJA, 29 March 2014—African leaders and key multilateral organizations are strengthening and broadening support for local production of essential medicines on the continent. The Seventh Joint African Union (AU) Conference of Ministers of Economy and Finance and the Economic Commission for Africa (ECA) Conference of African Ministers of Finance, Planning and Economic Development is being held in Abuja, Nigeria from 25-30 March.

Big Pharma abandons new tuberculosis drug research (post)

Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Global Fund and tiered medicines pricing under debate (post)

The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched an initiative with other agencies aimed at expanding global access to health products such as medicines. But the Fund has had some explaining to do about the initiative, which some say could encompass a plan to allow different prices based on national income levels.

UNITAID publishes full report on health implications of TPP (post)

UNITAID has published the full version of its report on “The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health.” The report finds a possible negative public health impact of the agreement under negotiation.

Nigeria: Global Fund tasks FG over increasing cases of untreated MDR-TB (post)

The Global Fund, a key partner in the National Tuberculosis and Leprosy Control Programme, NTBLCP, has raised alarm over the increasing cases of untreated multidrug-resistant tuberculosis, MDR-TB, in Nigeria.

TB drug approvals, distribution deal inches options forward, but MDR-TB treatment access still uncertain where needed most (post)

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was thanks to an agreement signed by drug maker Janssen and GDF procurement agent Strichting International Dispensary Association. It will make the drug, which is marketed as Sirturo, available to national TB programs and to private providers with treatment programs approved by national programs. Bedaquiline, the first new anti-tuberculosis medicine to win U.S. Food and Drug Administration approval in four decades also received approval from the European Medicines Agency the month before.

Page 3 of 67 · Total posts: 0

←First 2 3 4 Last→